Analyzing the Metrics of Stocks Advertised on CNBC
Looking into some of the companies advertised on CNBC shows their riskiness for stock investors.
Charles Rotblut
Stock Evaluator: Nexalin Technology, Inc. (NXL)
Nexalin Technology, Inc. NXL
$5.06
-0.04
-0.77%
September 18, 2026 10:15:13 AM
EST
Volume: 855
After Hours: $120.37
0.15
|
0.12%
November 10, 2021 7:59 PM
EST
Volume: 72,713
USD
NASD | DELAYED PRICE
| SECTOR | INDUSTRY |
| Health Care | Health Care Equipment & Supplies |
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Nexalin Technology, Inc., a medical device company, designs and develops neurostimulation products for the treatment of mental health epidemic in the United States and China. The company offers Generation 1, an easy-to-administer medical device which utilizes bioelectronic medical technology to treat anxiety, insomnia, and depression without the need for drugs or psychotherapy; and Generation 2 and Generation 3 headset devices for the treatment of depression, substance use disorder, traumatic brain injury, post-traumatic stress disorder, opioid addiction, alcoholism, and chronic pain, as well as alzheimer’s disease, and dementia. Nexalin Technology, Inc. is headquartered in Houston, Texas.
Commentary & Analysis
4 Undervalued Advanced Medical Equipment & Technology Stocks for Thursday, March 09
Discover the top 4 undervalued Advanced Medical Equipment & Technology stocks for Thursday, March 09 based on AAII’s Stock Grades.Jenna Brashear
3 Undervalued Advanced Medical Equipment & Technology Stocks for Tuesday, February 07
Discover the top 3 undervalued Advanced Medical Equipment & Technology stocks for Tuesday, February 07 based on AAII’s Stock Grades.Jack Gilleland
4 Undervalued Advanced Medical Equipment & Technology Stocks for Tuesday, January, 03
Discover the top 4 undervalued Advanced Medical Equipment & Technology stocks for Tuesday, January, 03 based on AAII’s Stock Grades.Jenna Brashear
Is Nexalin Technology Inc (NXL) Stock a Good Investment?
Learn more about Nexalin Technology Inc's (NXL) stock grades for Value and Growth and determine whether this Advanced Medical Equipment & Technology stock meets your investment needs.Cynthia McLaughlin
Financial Summary
| Share Statistics | NXL | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $3.7 | $366.1 | 2% |
|
| Shares Out (Mil) | 0.7 | 40.8 | 3% |
|
| Institutional Ownership | 26.8% | 83.3% | 12% |
|
| Float (Mil) | 0.5 | 35.1 | 1% |
|
| Beta | 3.98 | 0.87 | 99% |
|
| Avg Daily Volume (000s) | 17 | 299 | 20% |
|
| Price Change (52-week) |
(79.8%) | 63.3% | 7% |
|
| Growth | NXL | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | 8.4% | 11.8% | 52% |
|
| Net Income (5yr) | (19.3%) | (5.7%) | 21% |
|
| EPS (5yr) | 12.0% | 10.2% | 50 |
|
| Dividends (5yr) | 0.0% | 0.0% | 0% |
|
| Cash Flow (5yr) | 2.9% | (15.5%) | 66% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 1 | 1 | 1 | |
| Current EPS | ($2.700) | ($11.400) | ($9.300) | |
| Month Ago EPS | ($2.700) | ($11.400) | ($9.300) | |
| # Rev Up | na | 0 | na | |
| # Rev Down | na | 1 | na | |
| Three Months Ago EPS | ($2.700) | ($11.400) | ($9.300) | |
| Year/Year Chg | (15.0%) | (24.2%) | na | |
| Financials | NXL | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $0 | $119 | 0% |
|
| Net Income (TTM) (Mil) | ($9) | ($9) | 30% |
|
| EPS (TTM) | ($13.920) | ($0.400) | 4% |
|
| Operating Cash Flow (TTM) (Mil) | ($6) | ($3) | 23% |
|
| Net Cash Flow (TTM) (Mil) | $1 | $1 | 45% |
|
| Long-Term Debt (Q1) (Mil) | $0 | $23 | 0% |
|
| Enterprise Value (Q1) (Mil) | $4 | $376 | 5% |
|
| Valuation | NXL | Industry Median |
Percentile (All Stocks) |
|
| P/B | 2.46 | 2.80 | 59% |
|
| P/E | na | 25.7 | na |
|
| Dividend Yield | 0.0% | 0.0% | 0% |
|
| PEG (5yr hist) | na | 1.4 | na |
|
| Ratios | NXL | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | 86.2% | 58.5% | 92% |
|
| Net Margin | na | (6.9%) | na |
|
| ROA | (187.9%) | (12.3%) | 2% |
|
| ROE | (240.3%) | (11.1%) | 3% |
|
| Liabilities to Assets | 49.4% | 46.6% | 41% |
|
| F-Score | 4 | 4 | 33% |
|
Nexalin Technology, Inc. did not pass any screens on 9/17/2026.
